Inhibition of Alzheimer's β-amyloid induced vasoactivity and proinflammatory response in microglia by a cGMP-dependent mechanism

Experimental Neurology

Volumn 157, Issue 1, 1999, Pages 211-221

  Paris, Daniel ^a   Town, Terrence ^a   Parker, Timothy A ^a   Tan, Jun ^a   Humphrey, James ^a   Crawford, Fiona ^a   Mullan, Michael ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's disease; cGMP; Inflammation; LTB4; Microglia; Vasoconstriction

Indexed keywords

AMYLOID BETA PROTEIN; CYCLIC GMP; ENDOTHELIN 1;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; CELL TYPE; ENZYME ACTIVITY; GENETIC RISK; MICROGLIA; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SOLUBILIZATION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 0032934183     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7055     Document Type: Article

References (56)

1. Asada S., Kasuya Y., Sakurai T., Masaki T., Goto K. Endothelin-1-induced downregulation of ETB receptor mRNA: Participation of cAMP. J. Cardiovasc. Pharmacol. 26:1995;S272-S275.
2. Bolotina V. M., Najibi S., Palacino J. J., Cohen R. A. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 368:1994;850-853.
3. Bonkale W. L., Winblad B., Ravid R., Cowburn R. F. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. Neurosci. Lett. 187:1995;5-8.
4. i. Am. J. Physiol. 263:1992;C468-C473.
5. Clapp L., Gurney A. Modulation of calcium movement by nitroprusside in isolated vascular smooth muscle cells. Eur. J. Pharmacol. 418:1991;462-470.
6. Cohen R. A., Vanhoutte P. M. Endothelium-dependent hyperpolarization: beyond nitric oxide and cyclic cGMP. Circulation. 92:1995;3337-3349.
7. Coria F., Moreno A., Rubio I., Garcia M. A., Morato E., Mayor F. The cellular pathology associated with Alzheimer β-amyloid deposits in non-demented aged individuals. Neuropathol. Appl. Neurobiol. 19:1993;261-268.
8. Crawford F., Suo Z., Fang C., Sawar A., Su G., Arendash G., Mullan M. The vasoactivity of Aβ peptides. Ann. N. Y. Acad. Sci. 826:1997;3546.
9. Crawford F., Suo Z., Fang C., Mullan M. Characteristics of thein vitro. Exp. Neurol. 150:1998;159-168.
10. Domae M., Yamada K., Inoue T., Satoh M., Furukawa T. Endothelins stimulate cyclic AMP accumulation in the isolated rat anterior pituitary gland: Possible involvement of ETA receptor activation and prostaglandin E2 production. J. Pharmacol. Exper. Ther. 270:1994;55-60.
11. Douglas S. A., Ohlstein E. H. Signal transduction mechanisms mediating the vascular actions of endothelin. J. Vas. Res. 34:1997;152-164.
12. Ehrenreich H., Schilling L. New developments in the understanding of cerebral vasoregulation and vasospasm: The endothelin-nitric oxide network. Cleve. Clin. J. Med. 62:1995;105-116.
13. Ellis R. J., Olichney J. M., Thal L. J., Mirra S. S., Morris J. C., Beekly D., Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: The CERAD experience, Part XV. Neurology. 46:1996;1592-1596.
14. Famulari A. L., Marschoff E. R., Llesuy S. F., Kohan S., Serra J. A., Dominguez R. O., Repetto M., Reides C., Sacerdote de Lustig E. The antioxidant enzymatic blood profile in Alzheimer's and vascular diseases. Their association and a possible assay to differentiate demented subjects and controls. J. Neurol. Sci. 141:1996;69-78.
15. Faraci F. M., Brian J. E. Nitric oxide and regulation of the cerebral circulation. Stroke. 25:1994;692-703.
16. Farinelli S. E., Park D. S., Greene L. A. Nitric oxide delays the death of trophic factor-deprived PC12 cells and sympathetic neurons by a cGMP-mediated mechanism. J. Neurosci. 16:1996;2325-2334.
17. 2+. J. Pharmacol. Exp. Ther. 256:1991;371-377.
18. Fullerton D. A., Jaggers J., Piedalue F., Grover F. L., McIntyre R. C. Jr. Effective control of refractory pulmonary hypertension after cardiac operations. J. Thor. Cardiovas. Surg. 113:1997;363-368.
19. Furukawa K., Tawada Y., Shigekawa M. Regulation of the plasma membrane Ca2+ pump by cyclic nucleotides in cultured vascular smooth muscle cells. J. Biol. Chem. 263:1988;8058-8065.
20. Griffin W. S. T., Sheng J. G., Roberts G. W., Mrak R. E. Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54:1995;276-281.
21. Hirata M., Koshe K. P., Chang C., Ikebe T., Murad F. Mechanism of cyclic GMP inhibition of inositol phosphate formation in rat aorta segments and cultured bovine aortic smooth muscle cells. J. Biol. Chem. 265:1990;1268-1273.
22. Itagaki S., McGeer P. L., Akiyama H., Zhu S., Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease. J. Neuroimmunol. 24:1989;173-182.
23. Iuliano L., Pedersen J. Z., Rotilio G., Ferro D., Violi F. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Rad. Biol. Med. 18:1995;239-247.
24. Iuliano L., Colavita A. R., Camastra C., Bello V., Quintarelli C., Alessandroni M., Piovella F., Violi F. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br. J. Pharmacol. 119:1996;1438-1446.
25. Kittner B., Rossner M., Rother M. Clinical trials in dementia with propentofylline. Ann. N.Y. Acad. Sci. 826:1997;307-316.
26. Lefer D. J., Osborne J. A., Lefer A. M. Vascular responsiveness of constant flow perfused arteries with intact endothelium. Meth. Find. Exp. Clin. Pharmacol. 11:1989;5-10.
27. Levin E. R. Endothelins as cardiovascular peptides. Am. J. Neph. 16:1996;246-251.
28. Lincoln T. L., Cornwell T. M. Intracellular cyclic GMP receptor proteins. FASEB J. 7:1993;328-338.
29. Lis C. G., Gaviria M. Vascular dementia, hypertension, and the brain. Neurol. Res. 19:1997;471-480.
30. Lue L. F., Brachova L., Civin W. H., Rogers J. Inflammation, Abeta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J. Neuropathol. Exp. Neurol. 55:1996;1083-1088.
31. 2+. Am. J. Physiol. 263:1992;C461-C467.
32. Marcusson J., Rother M., Kittner B., Rossner M., Smith R. J., Babic T., Folnegovic-Smale V., Moller H. J., Labs K. H. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Dement. Geriatr. Cogn. Disord. 8:1997;320-328.
33. Markesbery W. R. Oxidative stress hypothesis in Alzheimer's disease. Free Rad. Biol. Med. 23:1997;134-147.
34. Mattson M. P., Tomaselli K. J., Rydel R. E. Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res. 621:1993;35-49.
35. Mattson M. P., Barger S. W., Furukawa K., Bruce A. J., Wyss-Coray T., Mark R. J., Mucke L. Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res. Rev. 23:1997;47-61.
36. McGeer P. L., Akiyama H., Itagaki S., McGeer E. G. Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16:1989;516-527.
37. McGeer P. L., Schulzer M., McGeer E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
38. Mielke R., Ghaemi M., Kessler J., Kittner B., Szelies B., Herholz K., Heiss W. D. Propentofylline enhances cerebral metabolic response to auditory memory stimulation in Alzheimer's disease. J. Neurol. Sci. 154:1998;76-82.
39. Moncada S., Palmer R. M. J., Higgs E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:1991;109-142.
40. Nishimura J., van Breemen C. Direct regulation of smooth muscle contractile elements by second messengers. Biochem. Biophys. Res. Commun. 163:1989;929-933.
41. Paris D., Town T., Parker T. A., Humphrey J., Mullan M. Isoform-specific vasoconstriction induced by Apolipoprotein E and modulation of this effect by Alzheimer's β-amyloid peptide. Neurosci. Lett. 256:1998;73-76.
42. 1-40. Exp. Neurol. 152:1998;116-122.
43. Picano E., Michelassi C. Chronic oral dipyridamole as a 'novel' antianginal drug: the collateral hypothesis. Cardiovasc. Res. 33:1997;666-670.
44. Prasad K. N., Hovland A. R., La Rosa F. G., Hovland P. G. Prostaglandins as putative neurotoxins in Alzheimer's disease. Proc. Soc. Exp. Biol. Med. 219:1998;120-125.
45. Pussard G., Gascard J. P., Gorenne I., Labat C., Norel X., Dulmet E., Brink C. Endothelin-1 modulates cyclic GMP production and relaxation in human pulmonary vessels. J. Pharmacol. Exp. Ther. 274:1995;969-975.
46. 2+. Brit. J. Pharmacol. 101:1990;722-726.
47. Rogers J., Kirby L. C., Hempielman S. R. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
48. Skoog I. The relationship between blood pressure and dementia: A review. Biomed. Pharmacother. 51:1997;367-375.
49. Sobey C. G., Faraci F. M. Effects of a novel inhibitor of guanylyl cyclase on dilator responses of mouse cerebral arterioles. Stroke. 28:1997;837-843.
50. Stewart W. F., Kawas C., Corrada M., Metter E. J. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:1997;626-632.
51. Suo Z., Humphrey J., Kundtz A., Sethi F., Placzeck A., Crawford F., Mullan M. Soluble Alzheimer's β-amyloid constricts the cerebral vasculaturein vivo. Neurosci. Lett. 257:1998;77-80.
52. Thomas T., Thomas G., McLendon C., Sutton T., Mullan M. β-amyloid mediated vasoactivity and vascular endothelial damage. Nature. 380:1996;168-171.
53. Thome J., Gsell W., Rosler M., Kornhuber J., Frolich L., Hashimoto E., Zielke B., Wiesbeck G. A., Riederer P. Oxydative-stress associated parameters (lactoferrin, superoxide dismutases) in serum of patients with Alzheimer's disease. Life Sci. 60:1997;13-19.
54. 2+. Biochem. J. 255:1988;855-863.
55. Vroom M. B., Pfaffendorf M., van Wezel H. B., van Zwieten P. A. Effect of phosphodiesterase inhibitors on human arteries in vitro. Br. J. Anaesth. 76:1996;122-129.
56. Wright L. C., Seybold J., Robichaud A., Adcock I. M., Barnes P. J. Phosphodiesterase expression in human epithelial cells. Am. J. Physiol. 275:1998;L694-700.